The trial will evaluate three escalating dose levels of the vaccine, in approximately 54 healthy adult volunteers and will follow each subject for six months post-vaccination.
Avant has designed the Ty800 vaccine to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of typhoid fever. The vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of S typhi.
“We are delighted that the NIAID is initiating clinical testing of our single-dose, oral Ty800 vaccine,” said Una Ryan, president and CEO of Avant. “The development of a safe and effective typhoid fever vaccine is important for protecting residents, travelers and military personnel from typhoid fever in endemic areas.”